PubMed

Final Version of 2009 AJCC Melanoma Staging and Classification.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK.

J Clin Oncol. 2009 Nov 16. [Epub ahead of print]PMID: 19917835 [PubMed - as supplied by publisher]Related articles

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA.

Clin Cancer Res. 2009 Nov 15;15(22):7036-44. Epub 2009 Nov 10.PMID: 19903780 [PubMed - in process]Related articles

Melanoma in pediatric, adolescent, and young adult patients.

Kirkwood JM, Jukic DM, Averbook BJ, Sender LS.

Semin Oncol. 2009 Oct;36(5):419-31.PMID: 19835737 [PubMed - in process]Related articles

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.

Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, Weitzel J, Daly MB, Benson AB, Kirkwood JM, O'Dwyer PJ, Sutphen R, Stewart JA, Johnson D, Larson GP.

Cancer Res. 2009 Sep 15;69(18):7459-65. Epub 2009 Sep 8.PMID: 19738052 [PubMed - indexed for MEDLINE]Related articles

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.

Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK.

Pigment Cell Melanoma Res. 2009 Oct;22(5):532-43. Epub 2009 Jun 29.PMID: 19659612 [PubMed - indexed for MEDLINE]Related articles

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA.

J Transl Med. 2009 Jul 29;7:68.PMID: 19640287 [PubMed - indexed for MEDLINE]Related articlesFree article

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45.PMID: 19534815 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of response to interferon therapy.

Gogas H, Kirkwood JM.

Curr Opin Oncol. 2009 Mar;21(2):138-43. Review.PMID: 19532015 [PubMed - indexed for MEDLINE]Related articles

Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors.

Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras MT, Tolstov Y, Gjoerup O, Mansukhani MM, Swerdlow SH, Chaudhary PM, Kirkwood JM, Nalesnik MA, Kant JA, Weiss LM, Moore PS, Chang Y.

Int J Cancer. 2009 Sep 15;125(6):1243-9.PMID: 19499546 [PubMed - indexed for MEDLINE]Related articles

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9.PMID: 19380770 [PubMed - indexed for MEDLINE]Related articles

Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.

Kirkwood JM, Tarhini AA.

J Clin Oncol. 2009 Jun 1;27(16):2583-5. Epub 2009 Apr 13. No abstract available. PMID: 19364958 [PubMed - indexed for MEDLINE]Related articles

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U.

J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6.PMID: 19349552 [PubMed - indexed for MEDLINE]Related articles

Highlights from the perspectives in melanoma XII conference.

Kirkwood JM, Eggermont A.

Pigment Cell Melanoma Res. 2009 Apr;22(2):156-65.PMID: 19302131 [PubMed - indexed for MEDLINE]Related articles

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L.

Clin Cancer Res. 2009 Feb 15;15(4):1443-51.PMID: 19228745 [PubMed - indexed for MEDLINE]Related articles

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.

Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM.

Cancer. 2009 Feb 15;115(4):859-68.PMID: 19140204 [PubMed - indexed for MEDLINE]Related articles

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A.

J Clin Oncol. 2009 Mar 1;27(7):1075-81. Epub 2009 Jan 12.PMID: 19139427 [PubMed - indexed for MEDLINE]Related articles

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81.PMID: 19105846 [PubMed - indexed for MEDLINE]Related articlesFree article

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ.

Nat Clin Pract Oncol. 2009 Feb;6(2):70-1. Epub 2008 Dec 17.PMID: 19092800 [PubMed]Related articles

Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.

Wang W, Edington HD, Rao UN, Jukic DM, Radfar A, Wang H, Kirkwood JM.

Clin Cancer Res. 2008 Dec 15;14(24):8314-20.PMID: 19088050 [PubMed - indexed for MEDLINE]Related articles

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM.

J Clin Oncol. 2009 Jan 1;27(1):38-44. Epub 2008 Dec 1.PMID: 19047287 [PubMed - indexed for MEDLINE]Related articles

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.

Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group.

J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10.PMID: 19001327 [PubMed - indexed for MEDLINE]Related articles

Adjuvant therapy of melanoma with interferon: lessons of the past decade.

Ascierto PA, Kirkwood JM.

J Transl Med. 2008 Oct 27;6:62. Review.PMID: 18954464 [PubMed - indexed for MEDLINE]Related articlesFree article

Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk.

Ding Y, Larson G, Rivas G, Lundberg C, Geller L, Ouyang C, Weitzel J, Archambeau J, Slater J, Daly MB, Benson AB, Kirkwood JM, O'Dwyer PJ, Sutphen R, Stewart JA, Johnson D, Nordborg M, Krontiris TG.

PLoS One. 2008;3(10):e3533. Epub 2008 Oct 27.PMID: 18953408 [PubMed - indexed for MEDLINE]Related articlesFree article

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.

Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM.

J Immunother. 2008 Oct;31(8):781-91.PMID: 18779741 [PubMed - indexed for MEDLINE]Related articles

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.

Tarhini AA, Kirkwood JM.

Expert Opin Biol Ther. 2008 Oct;8(10):1583-93.PMID: 18774925 [PubMed - indexed for MEDLINE]Related articles

A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.

Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS.

Cancer. 2008 Oct 1;113(7):1632-40.PMID: 18720480 [PubMed - indexed for MEDLINE]Related articlesFree article

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. Review.PMID: 18612161 [PubMed - indexed for MEDLINE]Related articles

Resolving "kinks" of chemotherapy in melanoma.

Moschos SJ, Chaudhary PM, Kirkwood JM.

J Natl Cancer Inst. 2008 Jun 18;100(12):833-5. Epub 2008 Jun 10. No abstract available. PMID: 18544737 [PubMed - indexed for MEDLINE]Related articlesFree article

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.

Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM.

Clin Cancer Res. 2008 Jun 1;14(11):3462-9.PMID: 18519778 [PubMed - indexed for MEDLINE]Related articlesFree article

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS.

J Clin Oncol. 2008 May 10;26(14):2292-8.PMID: 18467720 [PubMed - indexed for MEDLINE]Related articles

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT.

Clin Immunol. 2008 May;127(2):123-9. Review.PMID: 18405863 [PubMed - indexed for MEDLINE]Related articles

Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.

Wang W, Edington HD, Jukic DM, Rao UN, Land SR, Kirkwood JM.

Cancer Immunol Immunother. 2008 Sep;57(9):1315-21. Epub 2008 Apr 3.PMID: 18386001 [PubMed - indexed for MEDLINE]Related articles

STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.

Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, Kirkwood JM.

J Invest Dermatol. 2008 Aug;128(8):1997-2002. Epub 2008 Feb 28.PMID: 18305569 [PubMed - indexed for MEDLINE]Related articlesFree article

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.

Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL.

J Immunol. 2008 Mar 1;180(5):2967-80.PMID: 18292519 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.

Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS.

Cancer. 2008 Mar 1;112(5):1131-8.PMID: 18286511 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK; C-100-21 Study Group.

J Clin Oncol. 2008 Feb 20;26(6):955-62. Erratum in: J Clin Oncol. 2008 Aug 1;26(22): 3819. PMID: 18281670 [PubMed - indexed for MEDLINE]Related articles

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM.

Cancer. 2008 Mar 1;112(5):982-94. Review.PMID: 18236459 [PubMed - indexed for MEDLINE]Related articlesFree article

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM.

J Clin Oncol. 2008 Feb 1;26(4):527-34.PMID: 18235113 [PubMed - indexed for MEDLINE]Related articles

Management of metastatic melanoma.

Tawbi HA, Kirkwood JM.

Semin Oncol. 2007 Dec;34(6):532-45. Review.PMID: 18083377 [PubMed - indexed for MEDLINE]Related articles

Melanoma: immunotherapeutic approaches.

Agarwala SS, Kirkwood JM.

BioDrugs. 1999 Sep;12(3):193-208.PMID: 18031176 [PubMed - in process]Related articles

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC.

Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. Epub 2007 Nov 13. No abstract available. PMID: 18030300 [PubMed - indexed for MEDLINE]Related articles

Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.

Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM.

J Immunol. 2007 Dec 1;179(11):7932-40.PMID: 18025241 [PubMed - indexed for MEDLINE]Related articlesFree article

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

Vujanovic L, Mandic M, Olson WC, Kirkwood JM, Storkus WJ.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6796-806.PMID: 18006782 [PubMed - indexed for MEDLINE]Related articlesFree article

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Tarhini AA, Kirkwood JM.

Curr Opin Mol Ther. 2007 Oct;9(5):505-14. Review.PMID: 17932815 [PubMed - indexed for MEDLINE]Related articles

Integrins and cancer.

Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM.

Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):13-20. Review.PMID: 17927026 [PubMed - indexed for MEDLINE]Related articles

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.

Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.

J Clin Oncol. 2007 Sep 1;25(25):3802-7.PMID: 17761969 [PubMed - indexed for MEDLINE]Related articles

Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.

Moschos S, Kirkwood JM.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):451-8. Epub 2007 Aug 10. Review.PMID: 17693125 [PubMed - indexed for MEDLINE]Related articles

Oblimersen in the treatment of metastatic melanoma.

Tarhini AA, Kirkwood JM.

Future Oncol. 2007 Jun;3(3):263-71. Review.PMID: 17547520 [PubMed - indexed for MEDLINE]Related articles

Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.

Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM.

Melanoma Res. 2007 Jun;17(3):193-200.PMID: 17505265 [PubMed - indexed for MEDLINE]Related articles

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE.

Clin Cancer Res. 2007 Apr 15;13(8):2422-8.PMID: 17438101 [PubMed - indexed for MEDLINE]Related articlesFree article